JP2017513845A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513845A5
JP2017513845A5 JP2016562206A JP2016562206A JP2017513845A5 JP 2017513845 A5 JP2017513845 A5 JP 2017513845A5 JP 2016562206 A JP2016562206 A JP 2016562206A JP 2016562206 A JP2016562206 A JP 2016562206A JP 2017513845 A5 JP2017513845 A5 JP 2017513845A5
Authority
JP
Japan
Prior art keywords
disease
brain
disorder
risk
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016562206A
Other languages
English (en)
Japanese (ja)
Other versions
JP6498695B2 (ja
JP2017513845A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2015/050426 external-priority patent/WO2015162615A1/en
Publication of JP2017513845A publication Critical patent/JP2017513845A/ja
Publication of JP2017513845A5 publication Critical patent/JP2017513845A5/ja
Application granted granted Critical
Publication of JP6498695B2 publication Critical patent/JP6498695B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016562206A 2014-04-23 2015-04-22 キナゾリン骨格系の化合物、医薬組成物およびその使用方法 Expired - Fee Related JP6498695B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461982880P 2014-04-23 2014-04-23
US61/982,880 2014-04-23
PCT/IL2015/050426 WO2015162615A1 (en) 2014-04-23 2015-04-22 Quinazoline scaffold based compounds, pharmaceutical compositions and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2017513845A JP2017513845A (ja) 2017-06-01
JP2017513845A5 true JP2017513845A5 (https=) 2018-06-07
JP6498695B2 JP6498695B2 (ja) 2019-04-10

Family

ID=53276956

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016562206A Expired - Fee Related JP6498695B2 (ja) 2014-04-23 2015-04-22 キナゾリン骨格系の化合物、医薬組成物およびその使用方法

Country Status (6)

Country Link
US (1) US10035780B2 (https=)
EP (1) EP3134389B1 (https=)
JP (1) JP6498695B2 (https=)
CN (1) CN106458933B (https=)
IL (1) IL248578A0 (https=)
WO (1) WO2015162615A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6498695B2 (ja) 2014-04-23 2019-04-10 テクニオン・リサーチ・アンド・ディベロップメント・ファウンデーション・リミテッド キナゾリン骨格系の化合物、医薬組成物およびその使用方法
EP4611769A1 (en) * 2022-10-31 2025-09-10 Yeda Research and Development Co. Ltd Conditioning protocols for use with anti-viral central memory cd8+veto cells in haploidentical stem cell transplantation
WO2024095268A1 (en) * 2022-11-02 2024-05-10 Technion Research & Development Foundation Limited Translocator protein ligands and inflammatory diseases
CN116410180B (zh) * 2023-03-01 2024-09-10 青岛大学 4-氧代喹啉-3-甲酰胺衍生物及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2525595A1 (fr) 1982-04-27 1983-10-28 Pharmuka Lab Nouveaux derives d'arene et d'heteroarenecarboxamides et leur utilisation comme medicaments
FR2538388B1 (fr) 1982-12-24 1985-06-21 Pharmuka Lab Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments
US5716956A (en) 1995-06-07 1998-02-10 Bearsden Bearsden Bio, Inc. Dihydrophthalazine antagonists of excitatory amino acid receptors
DE19617863A1 (de) 1996-04-23 1997-10-30 Schering Ag Phthalazinderivate, deren Herstellung und Verwendung als Arzneimittel
JP2002505288A (ja) 1998-03-02 2002-02-19 コセンシス,インコーポレイテッド 置換キナゾリンおよびアナログならびにそれらの使用
JP2004256473A (ja) 2003-02-27 2004-09-16 Ono Pharmaceut Co Ltd エラスターゼ阻害活性を有する1,3,4−オキサジアゾール誘導体
CL2004000409A1 (es) 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
WO2008023357A1 (en) * 2006-08-22 2008-02-28 Technion Research And Development Foundation Ltd. Heterocyclic derivatives binding to the peripheral-type benzodiazepine receptor (pbr)
JP6498695B2 (ja) 2014-04-23 2019-04-10 テクニオン・リサーチ・アンド・ディベロップメント・ファウンデーション・リミテッド キナゾリン骨格系の化合物、医薬組成物およびその使用方法

Similar Documents

Publication Publication Date Title
JP7532561B2 (ja) 医学的障害の治療のためのアリール、ヘテロアリール及び複素環式化合物
JP2017513845A5 (https=)
Jenner Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease
Miyaoka et al. Possible antipsychotic effects of minocycline in patients with schizophrenia
JP2017516868A5 (https=)
DE60211343T2 (de) Derivate von triazolyl-imidazopyridine und von triazolylpurine als ligande des adenosine a2a rezeptoren und ihre verwendung als medicamente
FI3487505T3 (fi) Diaminofenotiatsiinien antaminen ja annostus
JP2017527532A5 (https=)
JP2013526544A5 (https=)
JP2014065696A5 (https=)
JP2004525142A5 (https=)
JP2010520889A5 (https=)
JP2019516756A5 (https=)
JP2014517050A5 (https=)
JP2011504474A5 (https=)
CA2815537A1 (en) Inhibitors of hepatitis c virus
JP2019534327A5 (https=)
CA2994162A1 (en) Glutamine antagonists for the treatment of cognitive deficits
JP2017523202A5 (https=)
JP2013224953A5 (https=)
JP2017535569A5 (https=)
JP2021535152A5 (https=)
JP2014508758A5 (https=)
JP2021504326A5 (https=)
RU2019125177A (ru) Новые производные амино-имидазопиридина в качестве ингибиторов янус-киназы и их фармацевтическое применение